Search Orphan Drug Designations and Approvals
-
| Generic Name: | ansuvimab-zykl |
|---|---|
| Trade Name: | EBANGA™ |
| Date Designated: | 05/08/2019 |
| Orphan Designation: | Treatment of Ebola Virus Disease |
| Orphan Designation Status: | Designated/Approved |
| Marketing Approval Date: | 12/21/2020 |
| Approved Labeled Indication: | EBANGA is indicated for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection. |
| Exclusivity End Date: | |
| Exclusivity Protected Indication* : | |
| Sponsor: |
Ridgeback Biotherapeutics, LP 3480 Main Highway Unit 402 Miami, Florida 33133 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
-
